Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli

J Infect Dis. 2012 Nov 15;206(10):1597-603. doi: 10.1093/infdis/jis567. Epub 2012 Sep 10.

Abstract

Background: We conducted a case-control study to identify risk factors for efflux overexpression, an important mechanism of fluoroquinolone resistance, among patients with fluoroquinolone-resistant Escherichia coli (FQREC) gastrointestinal tract colonization.

Methods: Three annual fecal surveillance surveys were performed hospital-wide, and all patients colonized with FQREC (levofloxacin minimum inhibitory concentration, ≥8 μg/mL) were included in the study. Cases and controls were defined on the basis of overexpression of the AcrAB efflux pump, as measured by the organic solvent tolerance (OST) assay. A multivariable logistic regression model was developed to identify risk factors for OST positivity among patients with FQREC colonization.

Results: Eighty-nine patients were colonized with FQREC: 44 (49.4%) and 45 (50.6%) patients had isolates that were OST-positive and OST-negative, respectively. On multivariable analyses, location on the surgical service was significantly associated with recovery of an OST-positive isolate (odds ratio, 7.36; 95% confidence interval, 1.82-29.7; P = .005). Furthermore, patients who had received a first-generation cephalosporin in the 30 days prior to sampling were less likely to have an OST-positive isolate (odds ratio, 0.20; 95% confidence interval, .04-.94; P = .04).

Conclusions: Among phenotypically identical FQREC isolates, different factors may drive the emergence of different resistance mechanisms. Further studies are needed to elucidate the relationship between antimicrobial use and specific resistance mechanisms.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Case-Control Studies
  • Drug Resistance, Multiple, Bacterial
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Escherichia coli Infections / epidemiology
  • Escherichia coli Infections / microbiology
  • Feces / microbiology
  • Fluoroquinolones / pharmacology*
  • Gastrointestinal Diseases / epidemiology
  • Gastrointestinal Diseases / microbiology
  • Gene Expression Regulation, Bacterial
  • Humans
  • Membrane Transport Proteins / genetics
  • Membrane Transport Proteins / metabolism*
  • Pennsylvania / epidemiology
  • Risk Factors

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Membrane Transport Proteins